RT Journal Article
SR Electronic
T1 Disease-associated antibody phenotypes and probabilistic seroprevalence estimates during the emergence of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.17.20155937
DO 10.1101/2020.07.17.20155937
A1 Dopico, Xaquín Castro
A1 Hanke, Leo
A1 Sheward, Daniel J.
A1 Christian, Murray
A1 Muschiol, Sandra
A1 Grinberg, Nastasiya F.
A1 Adori, Monika
A1 Vidakovics, Laura Perez
A1 Chang, Kim
A1 Khoenkhoen, Sharesta
A1 Pushparaj, Pradeepa
A1 Morro, Ainhoa Moliner
A1 Mandolesi, Marco
A1 Forsell, Mattias
A1 Coquet, Jonathan
A1 Corcoran, Martin
A1 Rorbach, Joanna
A1 Aleman, Soo
A1 Bogdanovic, Gordana
A1 McInerney, Gerald
A1 Allander, Tobias
A1 Wallace, Chris
A1 Murrell, Ben
A1 Albert, Jan
A1 Karlsson Hedestam, Gunilla B.
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.17.20155937.abstract
AB Serological studies are critical for understanding pathogen-specific immune responses and informing public health measures1,2. By developing highly sensitive and specific trimeric spike (S)-based antibody tests, we report IgM, IgG and IgA responses to SARS-CoV-2 in COVID-19 patients (n=105) representing different categories of disease severity. All patients surveyed were IgG positive against S. Elevated anti-SARS-CoV-2 antibody levels were associated with hospitalization, with IgA titers, increased circulating IL-6 and strong neutralizing responses indicative of intensive care status. Antibody-positive blood donors and pregnant women sampled during the pandemic in Stockholm, Sweden (weeks 14-25), displayed on average lower titers and weaker neutralizing responses compared to patients; however, inter-individual anti-viral IgG titers differed up to 1,000-fold. To provide more accurate estimates of seroprevalence, given the frequency of weak responders and the limitations associated with the dichotomization of a continuous variable3,4, we used a Bayesian approach to assign likelihood of past infection without setting an assay cut-off. Analysis of blood donors (n=1,000) and pregnant women (n=900) sampled weekly demonstrated SARS-CoV-2-specific IgG in 7.2% (95% Bayesian CI [5.1 – 9.5]) of individuals two months after the peak of spring 2020 COVID-19 deaths. Seroprevalence in these otherwise healthy cohorts increased steeply before beginning to level-off, following the same trajectory as the Stockholm region deaths over this time period.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this work was provided by a Distinguished Professor grant from the Swedish Research Council (agreement 532 2017-00968) and NIH (agreement SUM1A44462-02). CW and NFG are funded by the Wellcome Trust (WT107881) and MRC (MC_UP_1302/5)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Swedish Ethical Review Authority (registration no. 2020-01807).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData generated as part of the study, along with custom code for statistical analyses, is openly available via our GitHub repositories: https://github.com/MurrellGroup/DiscriminativeSeroprevalence/ and https://github.com/chr1swallace/seroprevalence-paper.